Myriad, AstraZeneca and MSD expand collaboration by Anna Smith | Apr 5, 2019 | News | 0 The expansion will use BRACAnalysis CDx to identify germline BRCA mutations. Read More
AZ deepens ties with Myriad on Lynparza companion test by Selina McKee | Jan 4, 2018 | News | 0 AstraZeneca has expanded its agreement with US group Myriad Genetics to identify women with advanced ovarian cancer most likely to benefit from its medicines. Read More